{"DataElement":{"publicId":"3874723","version":"1","preferredName":"Modified Immune Response Criteria Type","preferredDefinition":"Term to represent the response of an individual to treatment using modified standard immune-related response criteria.","longName":"TUM_MOD_IMM_RESP_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3874699","version":"1","preferredName":"Modified Immune Response Criteria","preferredDefinition":"The act of alteration or modification; changed or altered in form or character._Protected against infectious disease by either specific or non-specific mechanisms. (On-line Medical Dictionary)_Protected against infectious disease by either specific or non-specific mechanisms. (On-line Medical Dictionary)_Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._Criteria; a basis for comparison; a reference point against which other things can be evaluated.","longName":"MOD_IMM_RESP_CRIT","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3874696","version":"1","preferredName":"Change Immune","preferredDefinition":"The act of alteration or modification; changed or altered in form or character.:Protected against infectious disease by either specific or non-specific mechanisms. (On-line Medical Dictionary)","longName":"C25446:C17997","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immune","conceptCode":"C17997","definition":"Protected against infectious disease by either specific or non-specific mechanisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-665C-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3874697","version":"1","preferredName":"Immune Response Criterion","preferredDefinition":"Protected against infectious disease by either specific or non-specific mechanisms. (On-line Medical Dictionary):Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.:Criteria; a basis for comparison; a reference point against which other things can be evaluated.","longName":"C17997:C25755:C25466","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune","conceptCode":"C17997","definition":"Protected against infectious disease by either specific or non-specific mechanisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-666E-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-667F-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3874715","version":"1","preferredName":"Modified Immune Response Type","preferredDefinition":"1. any response of the immune system to an antigen including antibody production and/or cell-mediated immunity; 2. the response of the immune system to an antigen (immunogen) that leads to the condition of induced sensitivity; the immune response to the initial antigenic exposure (primary immune response) is detectable, as a rule, only after a lag period of from several days to two weeks; the immune response to a subsequent stimulus (secondary immune response) by the same antigen is more rapid than in the case of the primary immune response._Something distinguishable as an identifiable class based on common qualities.","longName":"MOD_IMM_RESP_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Overall irSD","valueDescription":"Overall immune response stable disease","ValueMeaning":{"publicId":"3874717","version":"1","preferredName":"Overall immune response stable disease","longName":"3874717","preferredDefinition":"The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions do not meet the criteria for complete remission, partial response (compared to baseline) or progressive disease (compared to nadir).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Overall Immune Related Response Criterion, Stable Disease","conceptCode":"C111086","definition":"The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions do not meet the criteria for complete remission, partial response (compared to baseline) or progressive disease (compared to nadir).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-6725-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E59407F2-673E-D041-E040-BB89AD4335D9","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Overall irPD","valueDescription":"Overall immune response progressive disease","ValueMeaning":{"publicId":"3874716","version":"1","preferredName":"Overall immune response progressive disease","longName":"3874716","preferredDefinition":"The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions increases by at least 20% (compared to nadir), and is confirmed by repeated, consecutive observations at least 4 weeks (normally done at 6 weeks) from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Overall Immune Related Response Criterion, Progressive Disease","conceptCode":"C111087","definition":"The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions increases by at least 20% (compared to nadir), and is confirmed by repeated, consecutive observations at least 4 weeks (normally done at 6 weeks) from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-6702-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E59407F2-671B-D041-E040-BB89AD4335D9","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Overall irPR","valueDescription":"Overall immune response partial response","ValueMeaning":{"publicId":"3874718","version":"1","preferredName":"Overall immune response partial response","longName":"3874718","preferredDefinition":"The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions has decreased by at least 30%.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Overall Immune Related Response Criterion, Partial Response","conceptCode":"C111085","definition":"The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions has decreased by at least 30%.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-6748-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E59407F2-6761-D041-E040-BB89AD4335D9","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Overall irCR","valueDescription":"Overall immune response complete response","ValueMeaning":{"publicId":"3874719","version":"1","preferredName":"Overall immune response complete response","longName":"3874719","preferredDefinition":"The evaluation of the antitumor response shows a complete disappearance of all lesions (whether measurable or not) and no new lesions.  All measurable lymph nodes also have a reduction in short axis diameter  to 10 mm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Overall Immune Related Response Criterion, Complete Remission","conceptCode":"C111084","definition":"The evaluation of the antitumor response shows a complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also have a reduction in short axis diameter to 10 mm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-676B-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E59407F2-6784-D041-E040-BB89AD4335D9","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"New non-measurable lesions","valueDescription":"New non-measurable lesions","ValueMeaning":{"publicId":"3874720","version":"1","preferredName":"New non-measurable lesions","longName":"3874720","preferredDefinition":"The finding of a growth smaller than 5 mm x 5 mm that was not present at the previous evaluation. Its presence does not indicate disease progression but precludes a determination of complete remission based on the modified overall immune related response criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Overall Immune Related Response Criterion, New Non-Measurable Lesion","conceptCode":"C111083","definition":"The finding of a growth smaller than 5 mm x 5 mm that was not present at the previous evaluation. Its presence does not indicate disease progession but precludes a determination of complete remission based on the modified overall immune related response criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-678E-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E59407F2-67A7-D041-E040-BB89AD4335D9","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"New measurable lesions","valueDescription":"New measurable lesions","ValueMeaning":{"publicId":"3874721","version":"1","preferredName":"New measurable lesions","longName":"3874721","preferredDefinition":"The identification of a lesion which has not been previously seen or characterized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New Lesion Identification","conceptCode":"C94522","definition":"The identification of a lesion which has not been previously seen or characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-67B1-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"TSESU","dateModified":"2023-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E59407F2-67CA-D041-E040-BB89AD4335D9","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3553263","version":"1","preferredName":"Immune Response Type","preferredDefinition":"1. any response of the immune system to an antigen including antibody production and/or cell-mediated immunity; 2. the response of the immune system to an antigen (immunogen) that leads to the condition of induced sensitivity; the immune response to the initial antigenic exposure (primary immune response) is detectable, as a rule, only after a lag period of from several days to two weeks; the immune response to a subsequent stimulus (secondary immune response) by the same antigen is more rapid than in the case of the primary immune response.:Something distinguishable as an identifiable class based on common qualities.","longName":"C17930:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Response Process","conceptCode":"C17930","definition":"Any immune system response of an organisms to an internal or invasive threat.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-43C1-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E59407F2-66EF-D041-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"REEVESD","dateModified":"2013-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Immune Related Response (irRC)","type":"Preferred Question Text","description":"Immune Related Response (irRC)","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E594A46A-F9A0-FEC5-E040-BB89AD43226D","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"REEVESD","dateModified":"2015-04-14","changeDescription":"Curated to support NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}